UOC
BCAB icon

UBS O'Connor’s BioAtla BCAB Stock Holding History

UBS O'Connor’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,195
Closed -$722K – 550
2024
Q1 		$722K Buy
4,195
+587
+16% +$72.9K 0.02% 306
2023
Q4 		$444K Sell
3,608
-5,246
-59% -$455K 0.01% 365
2023
Q3 		$753K Buy
8,854
+800
+10% +$102K 0.01% 360
2023
Q2 		$1.21M Buy
8,054
+3,153
+64% +$542K 0.03% 366
2023
Q1 		$657K Buy
+4,901
New +$883K 0.02% 443
2022
Q4 		– Sell
-2,240
Closed -$862K – 50
2022
Q3 		$862K Buy
+2,240
New +$733K 0.01% 763

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
SAM
Scion Asset Management Saratoga, California $1.38B AUM 43.96% 1-Year Est. Return

UBS O'Connor's BCAB Position: Q2 2024 in Review

UBS O'Connor sold out of BioAtla (BCAB) in Q2 2024, closing a stake of 4,195 shares — an estimated $722K sold.

UBS O'Connor first reported a position in BCAB in Q3 2022 and held it in 6 quarters. The position peaked at $1.21M in Q2 2023. 80 funds tracked by Wall St. Rank hold BCAB as of Q2 2024.

  • UBS O'Connor reported no remaining BioAtla position as of Q2 2024 after selling out during the quarter.
  • UBS O'Connor sold 4,195 BioAtla shares in Q2 2024, an estimated $722K.
  • UBS O'Connor first reported a position in BioAtla in Q3 2022 and held it in 6 quarters.
  • UBS O'Connor's BioAtla position peaked at $1.21M in Q2 2023.
  • 80 funds tracked by Wall St. Rank held BioAtla as of Q2 2024.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.